Boehringer Ingelheim signs manufacturing agreement with Apexigen

For process development and early stage clinical supply of monoclonal antibodies

Boehringer Ingelheim Biopharmaceuticals has signed a manufacturing supply agreement with Apexigen, an emerging US-based biopharmaceutical company dedicated to the discovery and development of therapeutic monoclonal antibodies.

As part of the agreement Boehringer Ingelheim will provide cell line development with the high expression BI-HEX system, full process and method development, scale-up and clinical phase I supply including fill and finish development for APX005, a humanised monoclonal antibody targeting CD40 for the treatment of cancers. APX005 has exhibited potent anti-tumour activities in preclinical studies.

‘This is an exciting project for Boehringer Ingelheim,’ said Simon Sturge, Boehringer Ingelheim's senior VP Biopharmaceuticals. ‘We are confident that our cutting edge production process technologies will advance Apexigen’s robust clinical programme.’

Boehringer Ingelheim Biopharma Contract Manufacturing is now represented by its new brand Boehringer Ingelheim BioXcellence, which offers tailormade contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (US).

Companies